<DOC>
	<DOCNO>NCT02483624</DOCNO>
	<brief_summary>This single center study patient inactive mild SLE perform determine safety , tolerability , pharmacodynamics DIM .</brief_summary>
	<brief_title>3,3'-Diindolylmethane Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This study single-blinded , placebo-controlled trial determine effect DIM supplementation patient SLE . The DIM supplement use BioResponse-DIM® ( BR-DIM® ) , absorption-enhanced formulation proven bioavailability animal test human trial . A total 30 individual enrol 14-month study . Ten patient randomly assign Low Dose Group [ daily dose 225 mg DIM BR-DIM ] . Ten patient randomly assign High Dose Group [ daily dose 375 mg DIM BR-DIM ] . Ten patient randomly assign match placebo group , 5 patient receive match placebo capsule equal use Low Dose active group , 5 receive match placebo equal use High Dose active group . Each active capsule deliver 75 mg DIM BR-DIM . Dosing span 52 week . BR-DIM comparably package placebo administer orally meal twice per day . Placebo subject randomize Low Dose group take 2 placebo capsule 1 capsule pm placebo subject randomize high dose group take 3 capsule 2 capsule pm . Low Dose active subject take 2 capsule 1 capsule pm . High Dose active subject take 3 capsule 2 capsule pm . Study subject randomly assign one four treatment group . Randomization procedure overseen staff North Shore Long Island Jewish General Clinical Research Center . The randomization schedule set Bio-Statistics unit . The Investigator contact Research Pharmacy North Shore University Hospital contact Bio-Statistics unit subject sign Informed Consent Form order learn treatment regimen subject assign . Patients control subject give appropriate amount study medication visit take home . Study personnel monitor compliance ask patient return unused study medication visit drug accountability . In addition , medication log keep study subject present study coordinator visit . The subject , study personnel , blind study drug assignment .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>3,3'-diindolylmethane</mesh_term>
	<criteria>Stable SLE disease activity period least 2 month prior Screening visit , base clinical judgment investigator History measurable antidsDNA , antiSm , RNP , SSA ( antiRo ) , SSB ( antiLa ) autoantibodies Age &gt; 18 &lt; 50 Ability understand requirement study , provide write consent , comply study protocol procedures A negative pregnancy test The use contraception fertile females A serum creatinine &lt; 1.8 mg/dL Serum hepatic transaminase &lt; 1.25 time upper limit normal Hemoglobin &gt; 9.5 , WBC &gt; 3.0 , neutrophil &gt; 1.2 ; platelet &gt; 90,000 Immunosuppressive therapy ( e.g . cyclophosphamide , cyclosporine , azathioprine , mycophenolate mofetil ) intravenous gamma globulin within 6 month study entry Prior receipt biologic agent , unless 9 month 4 halflives , whichever great , pass since last dose Prednisone &gt; 10 mg/day ( pharmacologic equivalent ) within 2 month randomization Pregnancy intent conceive study 3 month study completion Concurrent medication danazol , DHEA , medication affect estrogen level metabolism Nursing mother Oral contraceptive use The presence infection A history poor procedural compliance Receipt investigational drug within 60 day baseline Malignancy ( except basal cell carcinoma ) Dose change steroid , antimalarial drug , NSAID 's within 4 week randomization Peri postmenopausal state History clinical evidence active significant acute chronic disease ( i.e. , cardiovascular , pulmonary , untreated hypertension , anemia , gastrointestinal , hepatic , renal , neurological , cancer , infectious disease ) could confound result study put subject undue risk History medical disease , laboratory abnormality , condition would make subject ( opinion investigator ) unsuitable study Current drug alcohol addiction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>